Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone
administration in patients with opioid-induced bowel dysfunction (OBD).
Phase:
Phase 3
Details
Lead Sponsor:
Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc.